Skip to content

    Indivior Pharmaceuticals (INDV) stock price & financials

    View INDV earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+43.1% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $307.00M
    $298.00M
    $266.00M
    $302.00M
    $314.00M
    +2.3%
    $357.00M
    +19.8%
    $317.00M
    +19.2%
    $343.00M
    +13.6%
    Strengthening
    Operating Profit
    $35.00M
    $46.00M
    $66.00M
    $72.00M
    $43.00M
    +22.9%
    $81.00M
    +76.1%
    $137.00M
    +107.6%
    $160.00M
    +122.2%
    Strengthening
    Net Profit
    $22.00M
    $21.00M
    $47.00M
    $18.00M
    $42.00M
    +90.9%
    $103.00M
    +390.5%
    $89.00M
    +89.4%
    $122.00M
    +577.8%
    Strengthening
    EPS
    $0.16
    $0.38
    $0.15
    $0.34
    +112.5%
    $0.71
    +86.8%
    $1.02
    +580.0%
    Strengthening
    Other Income
    Interest
    $11.00M
    $12.00M
    $12.00M
    $15.00M
    $12.00M
    +9.1%
    $6.00M
    -50.0%
    $7.00M
    -41.7%
    $2.00M
    -86.7%
    Weakening
    Depreciation
    Profit before Tax
    $30.00M
    $38.00M
    $59.00M
    $62.00M
    $37.00M
    +23.3%
    $81.00M
    +113.2%
    $115.00M
    +94.9%
    $160.00M
    +158.1%
    Strengthening
    MarginsOPM
    11.4%
    15.4%
    24.8%
    23.8%
    13.7%
    +20.1%
    22.7%
    +47.0%
    43.2%
    +74.2%
    46.6%
    +95.7%
    Strengthening
    Tax
    26.7%
    44.7%
    18.6%
    71.0%
    -13.5%
    -150.7%
    -25.9%
    -158.0%
    22.6%
    +21.3%
    23.8%
    -66.5%
    Weakening
    ReturnsROIC
    -6.6%
    -6.3%
    -14.1%
    -5.4%
    -12.6%
    -90.9%
    -30.8%
    -390.5%
    -26.6%
    -89.4%
    -36.5%
    -577.8%
    Weakening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY22FY23FY24FY25TTM
    AssetsCash & Equivalents$774.00M$316.00M$319.00M$195.00M$222.00M
    Short-Term Investments
    Total Current Assets$1.26B$827.00M$652.00M$725.00M
    Net PP&E$124.00M$139.00M$170.00M$183.00M
    Goodwill$5.00M$2.00M$2.00M
    Intangibles
    Total Assets$1.76B$1.32B$1.20B$1.23B
    LiabilitiesTotal Current Liabilities$1.28B$924.00M$914.00M$868.00M
    Short-Term Debt$3.00M$18.00M$29.00M$0
    Long-Term Debt$237.00M$315.00M$290.00M$487.00M
    Long-Term Leases$34.00M$32.00M$22.00M$13.00M
    Total Liabilities$1.94B$1.65B$1.30B$1.44B
    EquityCommon Stock & APIC$68.00M$62.00M$62.00M$0
    Retained Earnings-$288.00M-$443.00M-$243.00M-$334.00M
    Total Equity-$15.00M-$184.00M-$337.00M-$98.00M-$208.00M
    HighlightsNet Cash / (Debt)$76.00M-$14.00M-$124.00M-$265.00M

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$4.00M-$300.00M$36.00M-$27.00M-$40.00M
    Cash from Investing-$222.00M-$95.00M$69.00M-$66.00M-$71.00M
    Cash from Financing-$101.00M-$64.00M-$102.00M-$30.00M-$174.00M
    SummaryCapital Expenditure-$5.00M-$8.00M-$29.00M-$66.00M-$71.00M
    Free Cash Flow-$9.00M-$308.00M$7.00M-$93.00M-$111.00M
    FCF Margin-1.0%-28.2%0.6%-7.5%-8.3%

    Ratios